CTSO Relative Valuation
CTSO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CTSO is overvalued; if below, it's undervalued.
Historical Valuation
Cytosorbents Corp (CTSO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -10.99. The fair price of Cytosorbents Corp (CTSO) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：0.74
Fair
-4.87
PE
1Y
3Y
5Y
Trailing
Forward
-16.92
EV/EBITDA
Cytosorbents Corp. (CTSO) has a current EV/EBITDA of -16.92. The 5-year average EV/EBITDA is -103.53. The thresholds are as follows: Strongly Undervalued below -816.84, Undervalued between -816.84 and -460.19, Fairly Valued between 253.12 and -460.19, Overvalued between 253.12 and 609.78, and Strongly Overvalued above 609.78. The current Forward EV/EBITDA of -16.92 falls within the Historic Trend Line -Fairly Valued range.
-11.79
EV/EBIT
Cytosorbents Corp. (CTSO) has a current EV/EBIT of -11.79. The 5-year average EV/EBIT is -11.25. The thresholds are as follows: Strongly Undervalued below -39.98, Undervalued between -39.98 and -25.61, Fairly Valued between 3.12 and -25.61, Overvalued between 3.12 and 17.49, and Strongly Overvalued above 17.49. The current Forward EV/EBIT of -11.79 falls within the Historic Trend Line -Fairly Valued range.
1.11
PS
Cytosorbents Corp. (CTSO) has a current PS of 1.11. The 5-year average PS is 3.22. The thresholds are as follows: Strongly Undervalued below -1.72, Undervalued between -1.72 and 0.75, Fairly Valued between 5.69 and 0.75, Overvalued between 5.69 and 8.16, and Strongly Overvalued above 8.16. The current Forward PS of 1.11 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Cytosorbents Corp. (CTSO) has a current P/OCF of 0.00. The 5-year average P/OCF is -10.76. The thresholds are as follows: Strongly Undervalued below -122.95, Undervalued between -122.95 and -66.86, Fairly Valued between 45.33 and -66.86, Overvalued between 45.33 and 101.43, and Strongly Overvalued above 101.43. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Cytosorbents Corp. (CTSO) has a current P/FCF of 0.00. The 5-year average P/FCF is -2.33. The thresholds are as follows: Strongly Undervalued below -58.87, Undervalued between -58.87 and -30.60, Fairly Valued between 25.94 and -30.60, Overvalued between 25.94 and 54.21, and Strongly Overvalued above 54.21. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Cytosorbents Corp (CTSO) has a current Price-to-Book (P/B) ratio of 5.14. Compared to its 3-year average P/B ratio of 4.00 , the current P/B ratio is approximately 28.77% higher. Relative to its 5-year average P/B ratio of 3.73, the current P/B ratio is about 37.87% higher. Cytosorbents Corp (CTSO) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -31.12%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -24.92% , the current FCF yield is about -100.00% lower.
5.14
P/B
Median3y
4.00
Median5y
3.73
-21.85
FCF Yield
Median3y
-31.12
Median5y
-24.92
Competitors Valuation Multiple
The average P/S ratio for CTSO's competitors is 0.00, providing a benchmark for relative valuation. Cytosorbents Corp Corp (CTSO) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 10.12%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CTSO decreased by 18.79% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 8.61M to 9.49M.
The secondary factor is the Margin Expansion, contributed 3.98%to the performance.
Overall, the performance of CTSO in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Cytosorbents Corp (CTSO) currently overvalued or undervalued?
What is Cytosorbents Corp (CTSO) fair value?
How does CTSO's valuation metrics compare to the industry average?
What is the current P/B ratio for Cytosorbents Corp (CTSO) as of Dec 05 2025?
What is the current FCF Yield for Cytosorbents Corp (CTSO) as of Dec 05 2025?
What is the current Forward P/E ratio for Cytosorbents Corp (CTSO) as of Dec 05 2025?